LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on CRNX stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cory Jubinville, PhD’s rating is based on several promising developments at Crinetics Pharmaceuticals. The company has successfully launched Palsonify, a treatment for acromegaly, with strong initial uptake. The rapid initiation of treatment, with the first patient receiving the drug just 11 days post-approval, and the salesforce’s effective reach to 95% of top healthcare providers, indicate a robust market entry.
Moreover, the reimbursement landscape appears favorable, with approximately 50% of filled prescriptions being covered by payors despite the high annual cost. The early prescription data is encouraging, showing significant patient transitions from injectables to Palsonify. Additionally, Crinetics has identified a substantial potential market expansion, with thousands of patients who have discontinued therapy or remain undiagnosed. The company’s solid financial position, with $1.1 billion on the balance sheet projected to fund operations until 2029, further supports the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $81.00 price target.